Skip to main content

Table 3 Characteristics of patients with or without crazy paving GGO

From: Prognostic significance of crazy paving ground grass opacities in non-HIV Pneumocystis jirovecii pneumonia: an observational cohort study

 

GGO with crazy paving, N = 29

GGO without crazy paving, N = 32

P-value

Age, years

70

(67–76)

67

(51–73)

0.06

Gender, female

18

(62.1%)

15

(46.9%)

0.31

Ever-smokers

10

(34.5%)

16

(50.0%)

0.41

Underlying diseases

 Autoimmune or collagen vascular diseases*

17

(58.6%)

19

(59.4%)

0.99

  Rheumatoid arthritis

11

(37.9%)

13

(40.6%)

0.99

 Malignancies**

11

(39.7%)

9

(28.1%)

0.59

  Haematological malignancies

3

(10.3%)

6

(18.8%)

0.48

  Solid cancers

8

(27.6%)

3

(9.4%)

0.10

 Renal diseases

1

(3.4%)

5

(15.6%)

0.20

 Renal transplantation

0

(0.0%)

1

(3.1%)

0.99

Corticosteroid use

25

(86.2%)

24

(75.0%)

0.34

Immunosuppressants use

8

(27.6%)

12

(37.5%)

0.43

Chemotherapeutic agents use

9

(31.0%)

7

(21.9%)

0.56

TMP/SMX prophylaxis

0

(0.0%)

2

(6.3%)

0.49

Initial symptoms

 Cough

16

(55.1%)

15

(46.9%)

0.31

 Dyspnoea

21

(72.4%)

17

(53.1%)

0.19

 Fever

24

(82.8%)

24

(75.0%)

0.54

Initial laboratory findings

 PaO2/FiO2 ratio

159

(126–206)

292

(226–357)

< 0.01

 AaDO2, mmHg

236

(50–369)

33

(25–56)

< 0.01

 Alb, g/dL

2.7

(1.0–4.3)

3.2

(1.6–4.9)

< 0.01

 WBC, cell/μL

7200

(5600–10,000)

7950

(6088–10,650)

0.39

 BUN

22

(17–35)

21

(16–30)

0.64

 LDH, IU/L

426

(368–555)

311

(273–389)

< 0.01

 KL-6, IU/μL

831

(522–1117)

439

(326–711)

< 0.01

 β-D-glucan, pg/mL

101

(41–373)

147

(55–404)

0.68

Diagnostic methods

 BAL

20

(69.0%)

25

(78.1%)

 

 BALF cytology positive

11

(37.9%)

6

(18.8%)

Treatments

 TMP/SMX

27

(93.1%)

28

(87.5%)

0.24

 Atovaquone

0

(0.0%)

1

(3.1%)

 

 Pentamidine

0

(0.0%)

3

(9.4%)

Treatment-related factors

 Adjuvant corticosteroid treatments

26

(89.7%)

27

(84.4%)

0.71

 Mechanical ventilation

3

(10.3%)

1

(3.1%)

0.34

Follow-up duration, days

25

(15–38)

21.5

(19–28)

0.51

In hospital mortality

17

(58.6%)

2

(6.2%)

< 0.01

  1. Abbreviations: Alb, albumin; WBC, white blood cells; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; KL-6, Krebs von den Lungen-6; BALF, bronchoalveolar lavage fluids*Autoimmune or collagen vascular diseases include rheumatoid arthritis.**Malignancies include haematological malignancies and solid cancers
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us